Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Curr Hematol Malig Rep. 2012 Sep;7(3):208-15. doi: 10.1007/s11899-012-0132-3.
We now recognize that the Epstein-Barr virus (EBV), which is a member of the γ- herpesvirus family, plays a pivotal role in the development of several lymphomas and lymphoproliferative disorders that include B-cell, T-cell and NK-cell processes. While over recent years, EBV associated lymphomas that arise in patients with known defects in cellular immunity are relatively well characterized, these diseases are becoming increasingly recognized in patients without overt immunodeficiency. Improved understanding of the biology of these lymphomas including elucidating the role that EBV plays in their pathogenesis has paved the way for improved therapies targeted at critical signaling pathways as well as the development of novel cellular therapies. In this review, we focus on recent progress that has been made in the biology and treatment of the rare EBV-associated disorder lymphomatoid granulomatosis (LYG) and also discuss other EBV-associated processes that occur in both immunocompetent and immunocompromised hosts.
我们现在认识到,属于 γ-疱疹病毒家族的 Epstein-Barr 病毒(EBV)在几种淋巴瘤和淋巴增生性疾病的发展中起着关键作用,这些疾病包括 B 细胞、T 细胞和 NK 细胞过程。虽然近年来,在已知存在细胞免疫缺陷的患者中发生的与 EBV 相关的淋巴瘤已得到相对较好的描述,但这些疾病在无明显免疫缺陷的患者中越来越被认识到。对这些淋巴瘤的生物学特性的深入了解,包括阐明 EBV 在其发病机制中的作用,为针对关键信号通路的改进治疗方法以及新型细胞治疗方法的发展铺平了道路。在这篇综述中,我们重点介绍了在生物学和治疗方面取得的最新进展罕见的 EBV 相关疾病淋巴样肉芽肿病(LYG),并讨论了在免疫功能正常和免疫功能低下宿主中发生的其他 EBV 相关过程。